Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 1997

View Archived Issues

Company Profile: Kos Pharmaceuticals

Cerebrus uses studies on Redux to design new antiobesity agents

International Murex: Q3 1997 highlights

Confirmatory trials of Alpha-Beta's Betafectin to begin

New agents in development for restenosis

Ganaxolone shows promise in phase II epilepsy and migraine trials

Nycomed Amersham merger now completed

Spotlight on thrombin inhibitors

Fibrinogen antagonists from Merck & Co.

Takeda describes new melatonin agonists

Quinoxalinediones for neurodegenerative/neurological disorders patented

Inhibitors of ECE prepared at Roussel Uclaf/INSERM

Novartis reports protein tyrosine kinase inhibitors for bone disorders

New taxoids from RPR

Preclinical and clinical profile of Searle's fibrinogen antagonist

TP-9201 covered by new U.S. patent

Lamifiban efficacy demonstrated in PARAGON trial

NCI supports R&D on antiangiogenic agents at Telios

Fast-track development of calanolide A as anti-AIDS drug

Prionics develops antibody useful for diagnosing and possibly treating prion diseases

RenaGel with and without calcium effective in ESRD

Efficacy of NC-100100 demonstrated in dogs

SB-234551 prevents radiocontrast-induced renal vasoconstriction in dogs

FDA clears Fortovase

Mechanism of action of triptolide investigated in human T-cells

Fibrinogen receptor occupancy, antiplatelet activity and safety of lefradafiban

LXR to commence pivotal trials with HK-Cardiosol

Phase Ia study with NGD-91-2 completed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.